Introduction
Primary IgA nephropathy (IgAN) is the most common glomerular disease worldwide, yet there is no international consensus for its pathological or clinical classification. Recently, a new classification for IgA nephropathy tried to identify specific pathological features that would predict the risk of progression of the nephropathy independent of clinical features [1] . The derivation set was based on retrospective clinical data and renal biopsy material from 265 patients (206 adults and 59 children) collected from eight countries. The estimated glomerular filtration rate (eGFR) values were evenly distributed within stages 1, 2 and 3 of the Kidney Disease Outcomes Quality (KDOQI) classification of chronic kidney disease (CKD). Only 16 patients (6%) had previous tonsillectomy. Prospective long-term studies are needed to validate the new classification.
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Lifelong follow-up with regular monitoring is recommended in IgAN, which is frequently progressive [2] . Since the pathogenesis of IgAN is obscure, specific treatment is not yet available and approaches have included tonsillectomy, steroids, immunosuppressants, angiotensinconverting enzyme inhibitors, angiotensin II receptor blockers, anticoagulants, fish oil and others [2] [3] [4] . Several retrospective studies have analysed the role of tonsillectomy in the treatment of IgAN [5] [6] [7] [8] [9] [10] [11] [12] [13] . Most contain a small number of patients, are non-randomized uncontrolled trials and provide conflicting data. Tonsillectomy did not have an independent impact on renal survival 10 years after biopsy [8] . Tonsillectomy associated with steroids and other immunosuppressants was found to be an independent factor in predicting remission of clinical findings and lack of renal progression [9] . In a retrospective study over 20 years of follow-up, renal survival at 240 months was 90% for the tonsillectomy group and 64% for the group without tonsillectomy. By multivariate analysis, tonsillectomy had a significant impact on renal outcome [10] .
Recently, Chen et al. evaluated both clinical remission and renal survival by tonsillectomy in IgAN patients over 130 months. At the multivariate analysis, there was no significant difference between the clinical remissions nor between the renal failure rate in patients with or without tonsillectomy [11] .
Several studies in Japan evaluated the effect of tonsillectomy in association with steroid pulse therapy (TSP). Recently, Miura et al. in a large survey of the treatment with IgAN found an average clinical remission rate (negative proteinuria and haematuria) of about 50% at 1 year after treatment. Predictive factors for resistance to TSP therapy were age at onset, amount of proteinuria, haematuria grade and pathological grade [12] .
A prospective, controlled study compared the effects of TSP therapy with those of steroid pulse alone in 55 patients with IgAN who were followed up for 54 months (35 underwent TSP therapy and 20 received steroid pulse monotherapy). None of TSP group achieved a 100% increase in serum creatinine, whereas one patient in monotherapy progressed to CKD stage 5. The multivariate analysis showed that the TSP therapy was approximately six-fold more effective than monotherapy in causing disappearance of proteinuria.
Although tonsillectomy has been expected to show efficacy, there has been little information about the effect of tonsillectomy on long-term renal survival in which the mean observation time exceeded 10 years. Moreover, no study reported the progression rate of IgAN in the early phases, considering the development of a mild renal dysfunction as the outcome. Despite the lack of information, the frequency of tonsillectomy in IgAN patients is increasing [13] .
The aim of the present study was to investigate whether tonsillectomy influences the clinical course of IgAN in the 20 years following renal biopsy. We considered IgAN patients who had tonsillectomy or not and compared them with control patients with mesangioproliferative glomerulonephritis (MesGN) free of IgA deposits who had tonsillectomy or not. We retrospectively evaluated the file of clinical records and estimated the incidence of progression to CKD stage 3 or higher in a cohort of patients who started the follow-up in CKD stage 1 or 2.
Methods

Study design
We performed a retrospective cohort study on the clinical records of 182 adult Caucasian outpatients with primary MesGN and IgAN who presented at renal biopsy with urinary abnormalities (haematuria with or without proteinuria of <3.5 g/day), in the absence of hypertension and in CKD stage 1 or 2. The eGFR values were calculated according to the KDOQI classification of CKD.
Patients underwent a visit every 6-12 months over 25 years , 12-300 months, mean follow-up 250 months) by the same nephrologist (AP). At each visit, both clinical and laboratory data were evaluated and recorded in a specific software (Nephro). The time of renal biopsy was considered the entry time into the follow-up. The last visit was within 31 December 2006. Only patients with an observation period >12 months were considered. Some of these patients underwent tonsillectomy. The end point was the progression from CKD stage 1-2 to stage 3 or higher. An informed consent was obtained from all subjects.
Statistical methods
Statistical analysis included the Student's t-test for unpaired data, the χ 2 test, the univariate survival analysis (log-rank test) and multivariate survival analysis (Cox model). Calculations were performed using the SPSS statistical package (ver. 16).
Results
We considered 182 adult patients (115 male and 67 female) of median age 25 years (range 16-57 years) with a biopsy-proven primary MesGN with mesangial IgA deposits (IgAN, n = 61, 39 male and 22 female) or without mesangial deposits (MesGN, n = 121, 76 male and 45 female). Patients underwent renal biopsy because of isolated haematuria (n = 31, 17%) or haematuria associated with proteinuria 0.2-3.5 g/day (n = 117, 64%). Persistent proteinuria was defined as the proteinuria of 0.2-3.5 g/day lasting for ≥1 year. Episodes of macrohaematuria were observed in 73 patients (40%). Other characteristics of the study population are reported in Tables 1 and 2 .
Sixty-four patients (35%) underwent tonsillectomy 6 months before or after the renal biopsy. A number of patients (n = 101, 55%) reported recurrent episodes of pharingo-tonsillitis (more than six episodes/year) at the time of renal biopsy. All patients who underwent tonsillectomy had recurrent pharingo-tonsillitis.
All patients at entry were without hypertension (blood pressure <140/90 mmHg). Seventy-five of them reported hypertension in their family. The range of the eGFR was 60-220 mL/min/1.73 m 2 ; 97 out of 182 patients (53%) were in CKD stage 1 (90-220 mL/min/1.73 m 2 ) and 85 (47%) were in stage 2 (60-89 mL/min/1.73 m 2 ). Prescription of anti-RAS drugs for proteinuria began after 1987 and was limited to 48 patients (26%) with a comparable frequency between groups (Table 2) . No patient was treated with steroids.
Characteristics of patients by tonsillectomy are reported in Tables 1 and 2 . At baseline, the distribution of most factors was similar in both groups. The group of patients who underwent tonsillectomy was older (30 vs 26 years), with less proteinuria (by 0.27 g/day) and less frequently with IgAN (25 vs 40%) compared to those without tonsillectomy.
We evaluated the early progression from a normal function to a moderate renal dysfunction in CKD stage 3, which was considered the outcome. The mean duration of follow-up was 250 months (range 12-300 months) in the whole group, 267 months (12-300 months) in the tonsillectomy group and 239 months (12-300 months) in the non-tonsillectomy group. The final eGFR was between 30 and 150 mL/min/1.73 m 2 , with 53 patients (29%) in stage 1, 87 (48%) in stage 2 and 42 (23%) in stage 3. The cumulative survival to progression to stage 3 was 88% (SE 3%) after 10 years, 71% (5%) after 20 years and 53% (7%) after 25 years. Univariate survival analysis is reported in Table 3 .
The survival to CKD progression did not differ between IgAN and MesGN groups (Figure 1 , P = 0.2). Interestingly, it was the same after 20 years: 72% (7%) in the IgAN group and 72% (6%) in the MesGN group.
Tonsillectomy was not significantly associated with CKD progression (Figure 2 ). The survival curves did not differ by tonsillectomy after stratification for the initial CKD stage (Figure 3 ) nor after stratification by nephropathy (IgAN and MesGN). Significant prognostic factors were age (P = 0.01), initial CKD stage (P = 0.03; Figure 4 ), proteinuria (P = 0.03), persistent proteinuria (P < 0.001; Figure 5 ) and diastolic blood pressure (P = 0.01; Table 3 ). Recurrent pharingo-tonsillitis was not associated with the progression of nephropathy.
In the multivariate analysis, there was no significant effect of tonsillectomy adjusted for the type of glomerulonephritis and for the other four factors that were significant at the univariate analysis (Table 3) , namely initial CKD stage, persistent proteinuria, diastolic blood pressure and age ( Figure 6 ). Only persistent proteinuria adjusted for the other factors was significantly associated with CKD progression [hazard ratio of 6.2, 95% confidence interval (CI) 3.1-12.7, P < 0.001] ( Table 4) . Daily proteinuria at the time of biopsy was also significant in the same model, but with a lower hazard ratio (3.6, 95% CI 1.2-11.1, P = 0.03).
For the sake of comparison with other studies, we also report how many patients, after reaching CKD stage 3, finally required dialysis or kidney transplantation: 11 out of 182 patients (6%), four of whom underwent tonsillectomy. Four patients died without progression of the nephropathy: two patients with acute myocardial infarction, one with lung cancer and one with liver cancer. One of these patients underwent tonsillectomy.
Discussion
This retrospective cohort study was conducted in 182 adult patients who were followed up for 25 years (mean 21 years) in a single centre by the same nephrologist. We evaluated the impact of tonsillectomy in the progression of IgAN and MesGN. The MesGN, a disease unrelated to mesangial IgA deposits, served as a control group for the pathological lesions and the progression of IgAN.
The overall survival to the progression from CKD stage 1-2 to CKD stage 3 was 88% after 10 years, 71% after 20 years and 53% after 25 years. The survival to progression was similar in IgAN and MesGN groups (72% after 20 years, Figure 1 ). Only 6% of patients (11 out of 182) progressed to CKD stage 5 after reaching stage 3. Literature reports that up to 30% of patients with IgAN will progress to stage 5 by 20 years [2] . The long-term outcome of MesGN is unknown. After 20 years, we documented a 30% progression to the moderate stage of renal insufficiency in both nephropathies (Figure 1) . The relative slow progression may be explained by our recruitment of homogeneous patients with a mild expression of the disease, that is with eGFR >60 mL/min/1.73 m 2 , with proteinuria <3.5 g/day and without hypertension. In literature, studies on follow-up of IgAN often include patients with eGFR at biopsy belonging to CKD stage 3 with wide ranges of proteinuria, including the nephrotic syndrome [1, 9, 10, 15] .
Established risk factors for progressive IgAN were equally distributed in patients with or without tonsillectomy (Tables 1 and 2 ). Only age (30 vs 26 years) and proteinuria (0.9 vs 0.6 g/day) were lower in the tonsillectomy group. In the multivariate Cox regression model with six clinical covariates, only persistent proteinuria had the strongest impact on renal outcome with a hazard ratio of 6.2 (95% CI 3.1-12.7). Tonsillectomy, also after adjustment for age, type of nephropathy, initial CKD stage, diastolic blood pressure and persistent proteinuria, did not influence the progression of the CKD stage in the long term (Table 4 ). Our result is in agreement with other studies [8, 10, 11] . A retrospective study from Germany reviewed the renal outcome in 55 patients with IgAN, 16 of whom had a prior tonsillectomy. Tonsillectomy did not have an independent impact on renal survival 10 years after biopsy [8] . Chen et al. evaluated both clinical remission and renal survival in 112 patients, 54 of whom underwent tonsillectomy. At the multivariate analysis, there was no significant difference between the clinical remissions of 46 vs 28% nor between the renal failure rate of 4 vs 12%, in those with vs without tonsillectomy, respectively [11] .
Our result is in disagreement with one retrospective study that was conducted in 118 patients in Japan and documented a significant influence of tonsillectomy in the IgAN progression over 20 years [10] . Forty-eight of these patients had a prior tonsillectomy. Survival to CKD stage 5 at 240 months was 90% for the tonsillectomy group and 64% for the group without tonsillectomy. By multivariate analysis, tonsillectomy had a significant impact on renal outcome (time of the first dialysis). The Cox model included tonsillectomy, mean blood pressure, serum creatinine, global glomerular sclerosis, interstitial lesion, crescent formation and steroid therapy. Of note, only interstitial lesion belongs to the list of four variables for prediction of renal outcome indicated by the new classification of IgAN: the mesangial hypercellularity score, segmental glomerulosclerosis, endocapillary hypercellularity and tubular atrophy/interstitial fibrosis [1] . However, renal survival curves only diverged between the two groups at >10 years from biopsy, as in our study (Figure 2 ). It is worth noting that after 20 years the survival to progression reached the same value of 72% in both nephropathies before crossing each other ( Figure 1 ). As in our study, most patients were not given any drugs during follow-up according to guidelines from two decades ago. Other studies found a significant effect of tonsillectomy associated with steroids in the progression of IgAN [9, 12, 13] . The effect of TSP therapy is apparently more effective in decreasing proteinuria and haematuria in the short term than in reducing the progression rate of the disease. However, it is difficult to establish the net effect of tonsillectomy independent of steroids.
To our knowledge, the present study on the efficacy of tonsillectomy in IgAN had the longest follow-up time with a mean follow-up duration >20 years (mean 250 months, range 12-300 months). It is also the first study evaluating the long-term progression of MesGN (no mesangial IgA Tonsillectomy in IgA nephropathydeposit), which resulted similar to IgAN, indirectly indicating the lack of any significant effect of mesangial IgA deposits (in part of tonsillar origin). Indeed, it has been suggested that tonsillectomy can improve IgA deposits and mesangial proliferation but cannot impact renal damage induced by other causes such as hypertension [15] . We also considered for the first time the early progression from CKD stages 1-2 (asymptomatic urinary abnormalities) to CKD stage 3. Interestingly, we found that after 20 years 30% of patients with either nephropathy progressed to a moderate renal dysfunction. The one significant factor predicting this progression was persistent proteinuria, i.e. proteinuria of 0.2-3.5 g/day that persisted for ≥1 year. Recently, proteinuria of 0.5-3.5 g/day that persists for ≥6 months has been indicated as the most powerful prognostic factor in IgAN [16] . In a well-documented study, there was a significant association between follow-up proteinuria and the mesangial hypercellularity score, segmental glomerulosclerosis and tubular atrophy/ Table 4 ) predicts the survival of the best case (age <25 years, CKD stage 1, diastolic blood pressure <80 mmHg and transient proteinuria). In panels c (MesGN) and d (IgAN), the pattern of covariates predicts the survival of the worst case (age >25 years, CKD stage 2, diastolic blood pressure >80 mmHg and persistent proteinuria). All other combinations of covariates generate survival curves lying between these extreme patterns.
interstitial fibrosis [1] . We could not test the importance of persistent haematuria because we only evaluated 31 patients with isolated haematuria. The limitations of this study must be recognized. It was a retrospective cohort study although the follow-up was done annually by the same team with accurate records and with precise identification of the outcome end point. Although randomized prospective controlled trials are very important, randomization of patients to tonsillectomy is hard to perform. As the renal biopsy material has not been reanalysed according to recent criteria [1] , the description of pathological feature of oldest biopsies was done with fewer details. Our selection of homogeneous patients with asymptomatic urinary abnormalities reflects the most frequent situation with IgAN but does not allow the extension of results to patients with more severe clinical situation. Our findings support the notion that it is the steroid component of tonsillectomy+steroids that confers benefit and that tonsillectomy alone is without benefit. But, since the study was not randomized, we could not control the selection bias for treatment as the subjects that were enrolled in the tonsillectomy group may have differed by the severity of background risk factors, although the difference of several factors did not reach statistical difference. Furthermore, subjects that were enrolled in the tonsillectomy+steroids observational studies of the literature may have been different from subjects enrolled in this study. Also, confounding by indication might be considerable even if we applied a multivariate analysis to control some confounding factors. Finally, we considered adult patients with an average age of 28 years (16-57 years) and compared the results with studies of similar mean age (e.g. [9] [10] [11] 13] ). The results from studies conducted in children may not be comparable with those achieved in adults due to different characteristics of the immune system and of the effect of immunosuppressive therapy.
At present, there is insufficient data to recommend tonsillectomy for IgAN patients. Those with recurrent bouts of tonsillitis may benefit, but if so, only at some time in the distant future [2] . So we recommend tonsillectomy following the indications of the otorhinolaryngologist based on the level of airway obstruction and repeated occurrence of acute tonsillitis. Authors supporting tonsillectomy [10, 15] observed that it was mainly useful in patients with mild IgAN, in whom the amount of proteinuria was <1 g/day and global glomerular sclerosis was <25%. When the amount of proteinuria was >1 g/day and global glomerular sclerosis was >25%, or crescent formation was >25%, patients could develop end-stage renal failure even if tonsillectomy was performed. Little information has been available about the side effects or complications of the operation in IgAN patients.
In conclusion, in this retrospective cohort study conducted in patients with normal renal function and asymptomatic urinary abnormalities, tonsillectomy had no influence on the progression of nephropathy up to 20 years after renal biopsy.
